Cambridge Cognition Holdings plc First Partnership in India and New Product Launch

Dr Steven Powell, Chief Executive Officer, Cambridge Cognition said: “This is the first time an effort has been made, on this scale, to provide Indian physicians with a sensitive, objective and user friendly digital cognitive screening tool. This will have significant impact on the ability to detect and treat neurological conditions in India with long term clinical benefits and substantial commercial potential.”

Cambridge Cognition Holdings plc (LOn: COG), which develops and markets neuroscience technology to assess brain health, announced a partnership with a major pharmaceutical company to deliver online neurological testing to patients in India using the Company’s cloud-based CANTAB Connect platform.

The contract includes an upfront payment of over £200,000 for the adaptation of an existing CANTAB digital cognitive health product for use by clinicians in the Indian healthcare market. As part of the product’s development a normative data study will be conducted with 1,500 Indian participants aged 10 – 90 years old before being validated in a clinical study with a further 1,500 patients – both studies being funded by the pharmaceutical partner.

Once validated, the sponsor will market the software to clinicians throughout India and pay an annual licence fee to Cambridge Cognition for use of the product plus additional annual fees per clinical user.

The need for a standardised, online screening assessment, such as CANTAB, which can be used by general practitioners, is believed to be important in combating the burden of neurological diseases in India.

Over 30 million people currently suffer from neurological disease in India creating a growing health crisis1. The problem is compounded by a paucity of trained medical experts, with only one neurologist per 1,250,000 population2. The result is patients being seen by general practitioners with limited knowledge about neurology, leading to low rates of diagnosis and poor treatment of disorders.

The new product being developed by Cambridge Cognition will enable general practitioners to consistently conduct expert neuropsychological assessments in 20 minutes without the need for formal training. Using gold standard CANTAB cognitive tests, the software, which is already in use in the UK NHS, will help to identify early signs of neuropsychological impairment, support timely diagnoses and provide instant feedback to patients at scale.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition forms new Scientific Advisory Board

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, is pleased to announce the formation of a Scientific Advisory Board. This expert board will provide scientific guidance and valuable market insights, primarily focusing

Cambridge Cognition Holdings

Cambridge Cognition Holdings Changes its Auditor to Crowe UK LL

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Board has approved the appointment of Crowe UK LLP as the Group’s new external auditor following a competitive

Cambridge Cognition Holdings

Cambridge Cognition strengthens balance sheet with £3 million loan

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Company has obtained a £3.0 million loan from Claret European Specialty Lending Company III, S.à r.l.  Claret specialises in

Cambridge Cognition Holdings

Cambridge Cognition Holdings Revision to Explanatory Note

Cambridge Cognition (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the explanatory note to Resolution 7 in the Notice of the Annual General Meeting (“AGM”) to be held on 28 June 2023

Cambridge Cognition Holdings

Cambridge Cognition publishes Annual Report and Accounts

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has confirmed that the Annual Report and Accounts for the year ended 31 December 2022 and the Notice of the Annual General

Cambridge Cognition Holdings

Cambridge Cognition growth strategy clearly paying off (VIDEO)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss prelim results for the year ended 31 December 2022. In this interview Matthew talks us through the result highlights, explains how the the acquisitions